Danaher shares are lower in Wednesday trading (April 22, 2026) as investors digest the company’s first-quarter 2026 update released April 21. While profitability metrics improved and Danaher slightly raised its full-year adjusted EPS range, the market reaction has turned negative as attention shifts to sluggish underlying revenue growth and pockets of demand weakness in Diagnostics and respiratory testing. (filecache.investorroom.com)

Danaher reported Q1 2026 revenue of $5.951 billion, with core revenue up 0.5% year over year, and adjusted diluted EPS of $2.06 (up 9.5%). Segment details showed Biotechnology core growth of 7%, Life Sciences core growth of 0.5%, and Diagnostics core revenue down 4%, a mix that reinforced the view that growth remains uneven across the portfolio. (filecache.investorroom.com)

Danaher lifted its 2026 adjusted EPS outlook to $8.35–$8.55 while keeping its full-year non-GAAP core revenue growth range at 3%–6%. Even with that EPS nudge higher, management commentary and disclosed drivers highlighted notable top-line headwinds: a lighter respiratory season (Cepheid respiratory revenue down roughly 25% year over year) and Diagnostics pressure tied to China pricing and procurement dynamics, which weighed on sentiment around near-term growth quality. (rttnews.com)

The post-earnings reset has also included multiple price-target changes, including a JPMorgan reduction to $245 from $275 while maintaining an Overweight rating, alongside other same-morning target adjustments listed across the Street. With the stock already down sharply year-to-date, the cluster of target trims adds to the perception that investors may need clearer evidence of accelerating demand—especially in Diagnostics and Life Sciences instruments—before the shares can stabilize. (marketscreener.com)